20 studies found for:    melanoma metastatic liver | Open Studies
Show Display Options
Rank Status Study
1 Unknown  TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients
Condition: Stage IV Melanoma Patients With Unresectable Liver Metastases
Intervention: Device: TACE using Drug Eluting Beads loaded with Doxorubicin
2 Recruiting RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy
3 Recruiting Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Conditions: Liver Metastases;   Lung Metastases;   Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Biological: ipilimumab;   Radiation: stereotactic radiosurgery;   Other: laboratory biomarker analysis
4 Recruiting An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
Condition: Malignant Melanoma
Intervention:
5 Recruiting Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan
Conditions: Advanced Melanoma;   Hepatitis B;   Hepatitis C
Intervention:
6 Unknown  Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Condition: Cancer
Interventions: Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: cryosurgery
7 Recruiting Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Melanoma;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Hepatocellular Carcinoma
Interventions: Drug: propranolol hydrochloride;   Other: Correlative Studies
8 Unknown  Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
Conditions: Melanoma;   Radiotherapy;   Metastatic Disease
Intervention: Procedure: Treatment of metastatic disease
9 Recruiting Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors
Conditions: Primary Brain Tumors;   Metastatic Malignant Neoplasm to Brain
Intervention: Drug: 4-Demethyl-4-cholestryloxycarbonylpenclomedine
10 Recruiting A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors
Condition: Neoplasms
Intervention: Drug: PF-04518600
11 Recruiting Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
Condition: Ocular Melanoma
Interventions: Drug: Sorafenib;   Device: Radioembolization with SIR-Spheres® (Yttrium Microspheres)
12 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Adult Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Neoplasm;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma;   Ureter Carcinoma;   Urethral Carcinoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
13 Recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
14 Recruiting Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Pleural Mesothelioma Malignant Advanced;   Peritoneal Mesothelioma Malignant Advanced;   Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC);   Metastatic Uveal Melanoma;   Hepatocellular Carcinoma (HCC);   Glioma
Intervention: Drug: ADI-PEG 20
15 Unknown  SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Condition: Malignant Melanoma
Interventions: Biological: SentoClone®;   Drug: Temodal® or Dacarbazine Medac®
16 Recruiting Collecting Solid Tumor Tissue to Identify New Treatments
Conditions: Gastrointestinal Cancer;   Liver Cancer;   Pancreatic Cancer;   Melanoma
Intervention:
17 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Conditions: Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
Interventions: Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
18 Not yet recruiting Survivorship Promotion In Reducing IGF-1 Trial
Conditions: Breast Cancer;   Prostate Cancer;   Lung Cancer;   Colon Cancer;   Melanoma of Skin;   Endometrial Cancer;   Liver Cancer;   Pancreatic Cancer;   Rectal Cancer;   Kidney Cancer;   Other Solid Malignant Tumors
Interventions: Drug: Metformin;   Behavioral: Coach Directed Behavioral Weight Loss;   Behavioral: Self-control weight loss
19 Unknown  Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors
Conditions: Renal Cell Carcinoma;   Melanoma;   Carcinoma, Hepatocellular
Intervention: Biological: immunotherapy with dendritic cells
20 Recruiting Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: ELIGARD

Indicates status has not been verified in more than two years